Name: Crohn'S Disease, an Issue of Gastroenterology Clinics of North America, 1e: Volume 46-3 (The Clinics: Internal Medicine) (en Inglés)
Price: 80470.00 CLP
Availability: InStock
Author: Edward V. Loftus Jr Md
ISBN: 9780323545549

portada Crohn'S Disease, an Issue of Gastroenterology Clinics of North America, 1e: Volume 46-3 (The Clinics: Internal Medicine) (en Inglés)

Formato

Libro Físico

Editorial

Elsevier

Autor

Edward V. Loftus Jr Md

Año

2017

Idioma

Inglés

Encuadernación

Tapa Dura

ISBN13

9780323545549

N° edición

Categorías

Enfermedades y trastornos

Crohn'S Disease, an Issue of Gastroenterology Clinics of North America, 1e: Volume 46-3 (The Clinics: Internal Medicine) (en Inglés)

Edward V. Loftus Jr Md (Autor) · Elsevier · Tapa Dura

Libro Físico

$ 80.470

$ 160.930

Ahorras: $ 80.460

50% descuento

Envío normal

Origen: Reino Unido (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 24 de Junio y el Jueves 04 de Julio.

Lo recibirás en cualquier lugar de Chile entre 1 y 3 días hábiles luego del envío.

Reseña del libro "Crohn'S Disease, an Issue of Gastroenterology Clinics of North America, 1e: Volume 46-3 (The Clinics: Internal Medicine) (en Inglés)"

Dr. Loftus is a widely recognized expert in the diagnosis and treatment of Crohn's disease. He has created an issue devoted the current state-of-the-art on Crohn's disease; authors have written comprehensive reviews on the latest research to inform clinical diagnosis and treatment. Articles are devoted to the following topics: Genetics; Epidemiology, natural history, and risk stratification of Crohn’s disease; The microbiome in Crohn’s disease: Role in pathogenesis and role of microbiome replacement therapies; Endoscopic and radiographic assessment of Crohn’s disease; Intestinal and non-intestinal cancer risk in Crohn’s disease; Sexuality, fertility, and pregnancy in Crohn’s disease; Interdisciplinary management of perianal Crohn’s disease; Targeting specific immunologic pathways in human inflammatory bowel disease; Evolution of treatment paradigms in Crohn’s disease; Preventing and managing postoperative recurrence of Crohn’s disease; Where and how to use anti-TNF agents and anti-integrins in Crohn’s disease; Ustekinumab and anti-interleukin-23 agents in Crohn’s disease; Update on therapeutic drug monitoring in Crohn’s disease; and Janus kinase antagonists and other novel small molecules for the treatment of Crohn’s disease. Readers will come away from this issue armed with the information they need to improve management of this disease as well as patient outcomes.